Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for chronic myocardial injury
ACTRN12620001256965Phase 2Terminated
- Sponsor
- Flinders University of South Australia
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic myocardial injury (CMI) comparing Dapagliflozin with Matching placebo (2 arms). Primary endpoint: Change in high-sensitivity troponin T concentration. Started Apr 2022; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
chronic myocardial injury (CMI)
Beyond the preview
Go deeper on ACTRN12620001256965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001256965.